Adrian Selim

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Paraneoplastic progressive encephalomyelitis with rigidity and myoclonus associated with monoclonal B-cell lymphocytosis in the setting of longstanding methotrexate use: case report

Fangzhi Jia, Mohammad Ruhul Amin, Gi Tae Kwon, Amir Mousapasandi et autres

Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare but debilitating disease within the stiff person syndrome (SPS) spectrum characterised by muscle rigidity, spasms, myoclonus, dysautonomia, and brainstem dysfunction. The exact pathogenetic mechanism is unclear, although there is an association with …

au (code pays fourni par la source)

2962 Paraneoplastic progressive encephalomyelitis with rigidity and myoclonus associated with monoclonal B-cell lymphocytosis in the setting of longstanding methotrexate use

Fangzhi Jia, Mohammad Ruhul Amin, Dai Pei, Adrian Selim et autres

Background Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare but debilitating disease within the stiff-person syndrome (SPS) spectrum and is characterised by muscle rigidity, spasms, myoclonus, dysautonomia and brainstem dysfunction. The exact pathogenetic mechanism is unclear, although there is an …

au (code pays fourni par la source)

Paraneoplastic Progressive Encephalomyelitis with Rigidity and Myoclonus Associated with Monoclonal B-Cell Lymphocytosis in the Setting of Longstanding Methotrexate Use: A Case Report and Literature Review

Fangzhi Jia, Mohammad Ruhul Amin, Gi Tae Kwon, Amir Mousapasandi et autres

au (code pays fourni par la source)

Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant

Wei Jiang, Leighton Clancy, Selmir Avdic, Gaurav Sutrave et autres

Virus-specific T-cells (VSTs) from third-party donors mediate short- and long-term antiviral effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or refractory viral infections. We investigated early administration of third-party VSTs, together with antiviral therapy in patients requiring treatment for …

au (code pays fourni par la source)

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Wei Jiang, Gaurav Sutrave, Selmir Avdic, Leighton Clancy et autres

Abstract Introduction: Reactivation of viruses such as cytomegalovirus (CMV) or Epstein Barr virus (EBV) after allogeneic hemopoietic stem cell transplant (aHSCT) is associated with increased non relapse mortality and a requirement for antivirals with mainly hemopoietic and renal toxicities that can further …

au (code pays fourni par la source)

An atypical case of Epstein–Barr virus‐positive plasma cell post‐transplant lymphoproliferative disorder successfully treated with adoptive cell therapy

Jessica Elliott, Selmir Avdic, Adrian Selim, Leighton Clancy et autres

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

au (code pays fourni par la source)

CAR-T cell therapy: practical guide to routine laboratory monitoring

Adrian Selim, Adrian Minson, Piers Blombery, Michael Dickinson et autres

au (code pays fourni par la source)

Chimeric antigen receptor T‐cell therapy for haematological malignancies

Adrian Selim, Constantine S. Tam

The advent of CAR T-cell therapy has seen significant improvements in survival and is a potential cure for patients with advanced haematological malignancies

au (code pays fourni par la source)

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, Wei Jiang, Selmir Avdic, Leighton Clancy et autres

Background Administration of partially HLA-matched third party virus-specific T cells (VST) from a cryopreserved cell bank is safe and effective after failure of standard antiviral therapy to resolve viral infection occurring after allogeneic stem cell transplantation (HSCT). Aim In this phase I …

au (code pays fourni par la source)

Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

Adrian Selim, Frank Alvaro, Catherine Cole, Chris Fraser et autres

BACKGROUND: Approximately one-third of children with acute myeloid leukemia (AML) relapse, requiring re-treatment and allogeneic hematopoietic stem cell transplantation (HSCT). Although achieving second complete remission (CR2) prior to HSCT is desirable, once CR2 is attained, it is unclear if there is any …

au, nz (code pays fourni par la source)

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia

Adrian Selim, Andrew S. Moore

au (code pays fourni par la source)